DB21623ApprovedInvestigationalSmall molecule
Zidesamtinib is a brain-penetrant, ROS1-selective kinase inhibitor with activity against ROS1 resistance mutations, indicated for locally advanced or metastatic ROS1-positive NSCLC after a prior ROS1 kinase inhibitor. ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence of resistance mutations, particularly the...
- Mechanism
- Curator reviewed
Pharmacologically active on Proto-oncogene tyrosine-protein kinase ROS
- Primary indication
- Zidesamtinib is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.Curator reviewed · 2 structured indications
- Formula / weight
- C22H22FN7O · 419.464 g/mol (avg)
- First approval
- United States, 2026
- Code names
- NU-0002362 · NU-0002362-009 · NU-2362-010 · NU-520 · NUV-520 · NVL-520
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
DTWUUAFTYSMNQX-GFCCVEGCSA-NSMILESCCN1N=CC2=C1C1=CN=C(N)C(O[C@H](C)C3=CC(F)=CC=C3C3=NN(C)N=C3C2)=C1What you can answer from here — as of September 23, 2026
5Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Zidesamtinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account